Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Market competition stories

Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Oct 23, 2026

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00
Oct 20, 2026

Dana-Farber and Beth Israel begin construction of $1.68 billion cancer hospital

Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting construction on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.

Oct 20, 2026·2 sources
00
Oct 16, 2026

UK competition regulator proposes strategic market status for Microsoft business software

Britain's Competition and Markets Authority proposed designating Microsoft with 'strategic market status' in business software, potentially enabling interventions in how the company bundles products and makes it harder for customers to switch providers.

Oct 16, 2026·2 sources
00
Sep 14, 2026

Novo Nordisk rebrands to Novo, updates logo

Novo Nordisk announced it is shortening its corporate name to Novo and updating its logo as part of a rebranding effort amid competition in the obesity drug market.

Sep 14, 2026·2 sources
00

Top claims

  • ▪Eli Lilly's lawyers argued in court filings that Eli Lilly's advertisements were factual and truthful because Eli Lilly ran head-to-head clinical trials that Novo Nordisk failed to match
  • ▪Novo Nordisk Chief Executive Officer Mike Doustdar made litigation against competitors part of his strategy to claw back market share
  • ▪Eli Lilly's advertisements state that Zepbound users lost an average of 50 pounds while Wegovy users lost 33 pounds, based on a 2025 head-to-head clinical study

Subtopics

Drug Policy, Pricing & Approval2Novo Nordisk2Pharmaceutical Industry2AI antitrust & competition1AI regulation & lawsuits1Autoimmune disease1Cancer & Oncology1Cancer and Cancer Treatment1Cancer treatment1Clinical trial design1Clinical trials1Corporate branding1Drug development1Eli Lilly1GLP-11Healthcare industry1Healthcare infrastructure1Microsoft1Neurological disorders1Obesity treatment1Oncology1Pharma1Pharmaceutical marketing1SEC regulation1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories